Meningococcal group A, C, Y and W-135 conjugate vaccine

Lee H Harrison; Nitin Mohan; Peter Kirkpatrick

doi:10.1038/nrd3194

Meningococcal group A, C, Y and W-135 conjugate vaccine

Nat Rev Drug Discov. 2010 Jun;9(6):429-30. doi: 10.1038/nrd3194.

Authors

Lee H Harrison¹, Nitin Mohan, Peter Kirkpatrick

Affiliation

¹ Infectious Diseases Epidemiology Research Unit, University of Pittsburgh Graduate School of Public Health and School of Medicine, Pittsburgh, Pennsylvania 15101, USA. [email protected]

PMID: 20514064
DOI: 10.1038/nrd3194

Abstract

In February 2010, a quadrivalent conjugate vaccine (Menveo; Novartis Vaccines and Diagnostics) was approved by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 in people aged 11-55 years.

MeSH terms

Adolescent
Adult
Child
Drug Approval*
Humans
Meningococcal Infections / prevention & control*
Meningococcal Vaccines / immunology*
Middle Aged
Neisseria meningitidis, Serogroup A / immunology*
Neisseria meningitidis, Serogroup C / immunology*
Neisseria meningitidis, Serogroup W-135 / immunology*
Neisseria meningitidis, Serogroup Y / immunology*
Vaccines, Conjugate

Substances

Meningococcal Vaccines
Vaccines, Conjugate